All Stories

  1. Reporting of D-dimer data in COVID-19: some confusion and potential for misinformation
  2. Mixing studies for lupus anticoagulant: mostly yes, sometimes no
  3. Laboratory testing for activated protein C resistance: rivaroxaban induced interference and a comparative evaluation of andexanet alfa and DOAC Stop to neutralise interference
  4. Danger of false negative (exclusion) or false positive (diagnosis) for ‘congenital thrombophilia’ in the age of anticoagulants
  5. Recent initiatives in harmonization of hemostasis practice
  6. On the complexity of hemostasis and the need for harmonization of test practice
  7. Towards harmonization of external quality assessment/proficiency testing in hemostasis
  8. Utility of the von Willebrand factor collagen binding assay in the diagnosis of von Willebrand disease
  9. Type 2M and Type 2A von Willebrand Disease: Similar but Different
  10. 2016 Eberhard F. Mammen Award Announcements: Part I — Most Popular Articles
  11. Type 2M von Willebrand disease - more often misidentified than correctly identified
  12. Editorial Compilation I
  13. Welcome to Seminars in Thrombosis & Hemostasis 2016: New (2014) Impact Factor and Most Highly Cited Articles
  14. 2015 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards
  15. 2015 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles
  16. “Bleeding in the jungle”
  17. Hot Topics VII
  18. The Platelet Function Analyser (PFA)-100 and von Willebrand disease: a story well over 16 years in the making
  19. Laboratory Testing in the Era of Direct or Non–Vitamin K Antagonist Oral Anticoagulants: A Practical Guide to Measuring Their Activity and Avoiding Diagnostic Errors
  20. Welcome to Seminars in Thrombosis & Hemostasis 2015: New (2013) Impact Factor and Most Highly Cited Articles
  21. The new and the old of heparin-induced thrombocytopenia
  22. Articles from Seminars in Thrombosis & Hemostasis (STH) Archives: Part II
  23. A Short History of Thrombosis and Hemostasis: Part II (40th Year Celebratory Issue)
  24. 2014 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards
  25. Aging Hemostasis: Changes to Laboratory Markers of Hemostasis As We Age—A Narrative Review
  26. Evaluating errors in the laboratory identification of von Willebrand disease in the real world
  27. Comparative sensitivity of commercially available aPTT reagents to mulga snake (Pseudechis australis) venom
  28. A Short History of Thrombosis and Hemostasis: Part I (40th Year Celebratory Issue)
  29. Articles from Seminars in Thrombosis & Hemostasis (STH) Archives
  30. Diagnosing von Willebrand Disease: A Short History of Laboratory Milestones and Innovations, Plus Current Status, Challenges, and Solutions
  31. Combined Administration of Antibiotics and Direct Oral Anticoagulants: A Renewed Indication for Laboratory Monitoring?
  32. Response to “Comment on E-Cigarettes and Cardiovascular Risk: Beyond Science and Mysticism”
  33. 2014 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles
  34. Laboratory testing for factor inhibitors
  35. von Willebrand disease and platelet disorders
  36. Interference from heterophilic antibodies in D-dimer assessment. A case report
  37. Influence of centrifuge brake on residual platelet count and routine coagulation tests in citrated plasma
  38. Artefactual “in-vitro coagulopathy” in a patient with non-Hodgkin lymphoma and lower gastrointestinal bleeding
  39. Quality in Hemostasis and Thrombosis — Part III
  40. Standardization and Harmonization of Antiphospholipid Antibody Assays
  41. External Quality Assessment/Proficiency Testing and Internal Quality Control for the PFA-100 and PFA-200: An Update
  42. A Tribute to Professor Jerry Koutts, MD (Syd), BS, FRACP, FRCPA (1944–2013)
  43. Welcome to Seminars in Thrombosis & Hemostasis 2014
  44. Hot Topics V
  45. Technological Advances in the Hemostasis Laboratory
  46. The futility of thrombophilia testing
  47. E-Cigarettes and Cardiovascular Risk: Beyond Science and Mysticism
  48. Problems and Solutions in Laboratory Testing for Hemophilia
  49. Editorial
  50. Technical Evaluation of the Novel Preanalytical Module on Instrumentation Laboratory ACL TOP: Advancing Automation in Hemostasis Testing
  51. Problems and Solutions in Laboratory Testing for Hemophilia
  52. Influence of Residual Platelet Count on Routine Coagulation, Factor VIII, and Factor IX Testing in Postfreeze-Thaw Samples
  53. Sample collection and platelet function testing
  54. Lupus anticoagulant testing – sometimes mixing is required
  55. Still more discussion on the journal impact factor
  56. 2013 Eberhard F. Mammen Award Announcements
  57. Laboratory testing for the new oral anticoagulants: a review of current practice
  58. Venous Thrombosis Associated with HMG-CoA Reductase Inhibitors
  59. Variability and diagnostic utility of antiphospholipid antibodies including lupus anticoagulants
  60. Quality in Hemostasis and Thrombosis, Part II
  61. Regulation in Hemostasis and Thrombosis: Part I—In Vitro Diagnostics
  62. Laboratory Evaluation of Von Willebrand Disease: Phenotypic Analysis
  63. Causes of Errors in Medical Laboratories
  64. External Quality Assessment of Factor VIII Inhibitor Assays
  65. Hot Topics IV
  66. Trials and tribulations in lupus anticoagulant testing
  67. Article downloads and citations: Is there any relationship?
  68. Welcome to Seminars in Thrombosis & Hemostasis 2013
  69. Interference in Coagulation Testing: Focus on Spurious Hemolysis, Icterus, and Lipemia
  70. Time for a conceptual shift in assessment of internal quality control for whole blood or cell-based testing systems? An evaluation using platelet function and the PFA-100 as a case example
  71. Massive Posttraumatic Bleeding: Epidemiology, Causes, Clinical Features, and Therapeutic Management
  72. Novel and Emerging Therapies: Thrombus-Targeted Fibrinolysis
  73. Quality in Hemostasis and Thrombosis—Part I
  74. Discard tube for coagulation testing
  75. New developments in the diagnosis and treatment of von Willebrand disease
  76. ABO blood group, hypercoagulability, and cardiovascular and cancer risk
  77. Laboratory hemostasis: milestones in Clinical Chemistry and Laboratory Medicine
  78. In Vitro and In Vivo Hemolysis
  79. Thrombotic and Hemorrhagic Syndromes Associated with Autoimmunity and Infection
  80. 2012 Eberhard F. Mammen Award Announcements
  81. External Quality Assurance for Heparin Monitoring
  82. Acquired Inhibitors of Coagulation Factors: Part I—Acquired Hemophilia A
  83. Acquired Inhibitors of Coagulation Factors: Part II
  84. Acquired Functional Coagulation Inhibitors: Review on Epidemiology, Results of a Wet-Workshop on Laboratory Detection, and Implications for Quality of Inhibitor Diagnosis
  85. Difficulties and pitfalls in the laboratory diagnosis of bleeding disorders
  86. Quality Standards for Sample Processing, Transportation, and Storage in Hemostasis Testing
  87. Quality Standards for Sample Collection in Coagulation Testing
  88. Patient Safety and Quality in Laboratory and Hemostasis Testing: A Renewed Loop?
  89. Laboratory identification of factor inhibitors: an update
  90. Paradoxical thrombosis part 1: factor replacement therapy, inherited clotting factor deficiencies and prolonged APTT
  91. Paradoxical thrombosis, part 2: anticoagulant and antiplatelet therapy
  92. The Antiphospholipid Syndrome: Diagnosis, Pathogenesis, Laboratory Testing, and Management
  93. Internal Quality Control and External Quality Assurance in Testing for Antiphospholipid Antibodies: Part I—Anticardiolipin and Anti-β2-Glycoprotein I Antibodies
  94. Internal Quality Control and External Quality Assurance in Testing for Antiphospholipid Antibodies: Part II—Lupus Anticoagulant
  95. Diagnosis of von Willebrand Disease
  96. Evaluating laboratory approaches to the identification of lupus anticoagulants: A diagnostic challenge from the RCPA Haematology QAP
  97. Relationship between short activated partial thromboplastin times, thrombin generation, procoagulant factors and procoagulant phospholipid activity
  98. Clinical audit of antiphospholipid antibody testing in tertiary practice: towards improved relevance in thrombophilia investigations
  99. Biological therapies for von Willebrand disease
  100. Coagulopathies and Thrombosis: Usual and Unusual Causes and Associations, Part VI
  101. Coffee Intake and Cardiovascular Disease: Virtue Does Not Take Center Stage
  102. Hemostatic Properties of the Lymph: Relationships with Occlusion and Thrombosis
  103. Hot Topics III
  104. Welcome to Seminars in Thrombosis & Hemostasis 2012
  105. 2B or not 2B? Masquerading as von Willebrand disease?
  106. Pre-analytical Variables in Coagulation Testing Associated With Diagnostic Errors in Hemostasis
  107. The new oral anticoagulants and the future of haemostasis laboratory testing
  108. Proficiency testing/external quality assurance for the PFA-100®
  109. Influence of mechanical trauma of blood and hemolysis on PFA-100 testing
  110. Biomedical research platforms and their influence on article submissions and journal rankings: An update
  111. Standards and reference materials for the anticardiolipin and anti-β2glycoprotein I assays: A report of recommendations from the APL Task Force at the 13th International Congress on Antiphospholipid Antibodies
  112. International consensus guidelines on anticardiolipin and anti–β2‐glycoprotein I testing: Report from the 13th International Congress on Antiphospholipid Antibodies
  113. Antisense therapy in the treatment of hypercholesterolemia
  114. Laboratory testing of anticoagulants: the present and the future
  115. A robust method for testing urinary iodine using a microtitre robotic system
  116. Iodine Deficiency: Current Aspects and Future Prospects
  117. Direct-to-consumer testing: more risks than opportunities
  118. Holiday Thrombosis
  119. Seminars in Thrombosis & Hemostasis 2010: Impact Factor and Highest-Cited Articles from 2008 to 2009
  120. Coagulopathies and Thrombosis: Usual and Unusual Causes and Associations. Part V.
  121. Diagnosis and classification of von Willebrand disease
  122. von Willebrand Factor Assay Proficiency Testing Continued
  123. Thrombocytopenic Platelet Disorders
  124. Diagnosis of type 1 vs. 2A and 2M von Willebrand disease
  125. Cycling: To Race or to Live – Reflections on Skewed Priorities?
  126. Distinguishing types 1 and 2M von Willebrand disease
  127. Diagnosis and Management of v on Willebrand Disease in Australia
  128. von Willebrand Disease: Local Diagnosis and Management of a Globally Distributed Bleeding Disorder
  129. 2011 Eberhard F. Mammen Award Announcements
  130. Michael Dawson, B. Pharm. (Hon), Ph.D. (1954–2010)
  131. v on Willebrand Disease: Local Diagnosis and Management of a Globally Distributed Bleeding Disorder
  132. Assessment for antithrombin deficiency in the real world
  133. Regulation of in vitro diagnostics (IVDs) for use in Australian pathology laboratories: a gloomy outlook for future pathology testing in this country?
  134. Inherited disorders of blood coagulation
  135. Laboratory testing and/or monitoring of the new oral anticoagulants/antithrombotics: for and against?
  136. Laboratory diagnostics and appropriate care of people with haemophilia
  137. Inherited and acquired factor V deficiency
  138. A clinical audit of congenital thrombophilia investigation in tertiary practice
  139. External quality assurance for the PFA‐100®
  140. Prevention of Venous Thromboembolism: Focus on Mechanical Prophylaxis
  141. Coagulopathies and Thrombosis: Usual and Unusual Causes and Associations, Part IV
  142. Obstructive Sleep Apnea Syndrome and Cardiovascular Diseases
  143. Laboratory Diagnosis of von Willebrand Disease: The Phenotype
  144. Venous Thromboembolism in Chronic Liver Disease
  145. Glycoprotein IIb/IIIa inhibitors: an update on the mechanism of action and use of functional testing methods to assess antiplatelet efficacy
  146. Functional analysis of three recombinant A1-VWF domain mutants in comparison to wild type and plasma-derived VWF facilitates subtyping in type 2 von Willebrand disease
  147. More on preanalytical variables affecting platelet function testing using light transmittance aggregometry
  148. Laboratory testing for the antiphospholipid syndrome: making sense of antiphospholipid antibody assays
  149. Hormones, Endocrine Disorders, and Hemostasis
  150. The Spectrum of Coagulation Abnormalities in Thyroid Disorders
  151. Rethinking the diagnosis of von Willebrand disease
  152. Coagulation update: What's new in hemostasis testing?
  153. Regulation of in vitro diagnostics (IVDs) for use in clinical diagnostic laboratories: towards the light or dark in clinical laboratory testing?
  154. Interaction of factor VIII and von Willebrand factor and the identification of type 2N von Willebrand disease
  155. Studies on in vitro hemolysis and utility of corrective formulas for reporting results on hemolyzed specimens
  156. Laboratory investigation of lupus anticoagulants: mixing studies are sometimes required
  157. Validation of improved performance characteristics for the automated von Willebrand factor ristocetin cofactor activity assay
  158. Farewell to 2010!
  159. Global Hemostasis: New Approaches to Patient Diagnosis and Treatment Monitoring
  160. Winners of the 2010 Eberhard F. Mammen Award for Most Popular Article during 2008–2009
  161. Hemolytic Uremic Syndrome
  162. C-reactive protein and venous thromboembolism: causal or casual association?
  163. Recombinants in Thrombosis and Hemostasis: From Basic Research to Clinical Therapy
  164. Recombinant Platelet Factor 4: A Therapeutic, Anti-Neoplastic Chimera?
  165. 2009 Eberhard F. Mammen Young Investigator Award Winners
  166. Thrombotic Complications of Erythropoiesis-Stimulating Agents
  167. Shortened activated partial thromboplastin time: causes and management
  168. Quality issues in laboratory haemostasis
  169. Laboratory identification of factor VIII inhibitors in the real world: the experience from Australasia
  170. Laboratory Testing in Disseminated Intravascular Coagulation
  171. Laboratory testing in pharmacies
  172. Improving the harmonisation of the International Normalized Ratio (INR): time to think outside the box?
  173. UNSUSPECTED COAGULOPATHY RARELY PREVENTS IV THROMBOLYSIS IN ACUTE ISCHEMIC STROKE
  174. Laboratory medicine and natural disasters: are we ready for the challenge?
  175. The antiphospholipid syndrome: a large elephant with many parts or an elusive chameleon disguised by many colours?
  176. Problems in laboratory testing: hemophilia and beyond
  177. Under-Recognized Significance of Endothelial Heterogeneity: Hemostasis, Thrombosis, and Beyond
  178. Proteomic analysis of venous thromboembolism
  179. Genetic testing in von Willebrand disease: reply to rebuttal
  180. Biochemical markers for the diagnosis of venous thromboembolism: the past, present and future
  181. Platelets, Inflammation and Cardiovascular Diseases. New Concepts and Therapeutic Implications
  182. A laboratory evaluation into the short activated partial thromboplastin time
  183. Mild hemophilia A
  184. Contemporary platelet function testing
  185. Coagulopathies and Thrombosis: Usual and Unusual Causes and Associations, Part III
  186. Influenza and Cardiovascular Disease: Does Swine-Origin, 2009 H1N1 Flu Virus Represent a Risk Factor, an Acute Trigger, or Both?
  187. Moderate Red Wine Consumption and Cardiovascular Disease Risk: Beyond the “French Paradox”
  188. Quality in coagulation and haemostasis testing
  189. Hemophilia, cancer and cardiovascular disease
  190. Glanzmann thrombasthenia: An update
  191. Genetic testing for von Willebrand disease: the case against
  192. Laboratory reporting of hemostasis assays: the final post-analytical opportunity to reduce errors of clinical diagnosis in hemostasis?
  193. Identification and prevalence of von Willebrand disease type 2N (Normandy) in Australia
  194. Current clinical and laboratory practice for the investigation of the antiphospholipid syndrome: findings from the 2008 Australasian antiphospholipid antibody survey
  195. Emanuele Favaloro (1920–2009) and Francesca Favaloro (1922–2009)
  196. Farewell to 2009!
  197. Identification, Pathogenesis, and Treatment of Factor Inhibitors
  198. Investigations from External Quality Assurance Programs Reveal a High Degree of Variation in the Laboratory Identification of Coagulation Factor Inhibitors
  199. Winners of the Inaugural Eberhard F. Mammen Award for Most Popular Article
  200. Coagulopathies and Thrombosis: Usual and Unusual Causes and Associations, Part II
  201. Laboratory Investigation of Thrombophilia: The Good, the Bad, and the Ugly
  202. Unsuspected Triggers of Venous Thromboembolism—Trivial or Not So Trivial?
  203. Prostate-Specific Antigen, Prostate Cancer, and Disorders of Hemostasis
  204. The Bidirectional Relationship of Cancer and Hemostasis and the Potential Role of Anticoagulant Therapy in Moderating Thrombosis and Cancer Spread
  205. Potential supplementary utility of combined PFA-100 and functional von Willebrand factor testing for the laboratory assessment of desmopressin and factor concentrate therapy in von Willebrand disease
  206. D-Dimer Measurement and Laboratory Feedback
  207. Laboratory assessment and perioperative management of patients on antiplatelet therapy: From the bench to the bedside
  208. Relationship between 24-h air pollution, emergency department admission and diagnosis of acute coronary syndrome
  209. The role of ethnicity, age and gender in venous thromboembolism
  210. Time to seek further clarity in the molecular analysis of von Willebrand disease?
  211. Rare Bleeding Disorders
  212. Rodger L. Bick, M.D., Ph.D., FACP (1943–2008)
  213. Coagulopathies and Thrombosis: Usual and Unusual Causes and Associations, Part I
  214. Mental Depression and Cardiovascular Disease: A Multifaceted, Bidirectional Association
  215. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: Differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?
  216. Internal Quality Control and External Quality Assurance of Platelet Function Tests
  217. Diagnostic Evaluation of Platelet Disorders: The Past, the Present, and the Future
  218. Welcome to the First Issue of Seminars in Thrombosis and Hemostasis for 2009
  219. Milestones and Perspectives in Coagulation and Hemostasis
  220. Relationship between activated partial thromboplastin time, heparin and potassium levels
  221. Laboratory Diagnostics and Therapy in Thrombosis and Hemostasis: From Bedside to Bench to Bedside
  222. Toward a New Paradigm for the Identification and Functional Characterization of von Willebrand Disease
  223. High Rate of Deficiency in the Amino Acids Tryptophan and Histidine in People with Wounds
  224. The missing link between genotype, phenotype and clinics
  225. Pharmacogenetics of vitamin K antagonists: useful or hype?
  226. The Journal Impact Factor: don't expect its demise any time soon
  227. Diagnosis of von willebrand disease (VWD): towards a new paradigm for the identification and functional characterisation of VWD
  228. One-stage clotting versus chromogenic assays for assessing recombinant factor VIII: two faces of a haemostasis coin
  229. Survey on the prevalence of hemolytic specimens in an academic hospital according to collection facility: opportunities for quality improvement
  230. Epidemiological association between fasting plasma glucose and shortened APTT
  231. Laboratory Evaluation of von Willebrand Disease: Phenotypic Analysis
  232. Aspirin ‘responsiveness’, ‘nonresponsiveness’ or ‘resistance’: a putative role for von Willebrand factor?
  233. Welcome to a Special Issue of Seminars in Thrombosis and Hemostasis —The Closing Issue for 2008
  234. A Tribute to Eberhard F. Mammen, M.D. (1930–2008)
  235. Clinical Utility of the PFA-100
  236. Activated Partial Thromboplastin Time: New Tricks for an Old Dogma
  237. Laboratory Diagnostics in Thrombosis and Hemostasis: The Past, the Present, and the Future
  238. Standardization of the INR: How Good Is Your Laboratory's INR and Can It Be Improved?
  239. Preanalytical and Postanalytical Variables: The Leading Causes of Diagnostic Error in Hemostasis?
  240. Dark chocolate: consumption for pleasure or therapy?
  241. Hyperthyroidism is associated with shortened APTT and increased fibrinogen values in a general population of unselected outpatients
  242. Salbutamol in Athletes
  243. Genetics of type 2B von Willebrand Disease: “True 2B,” “tricky 2B,” or “Not 2B.” What Are the Modifiers of the Phenotype?
  244. A better approach to monitoring of therapy in von Willebrand disease?
  245. Differential identification of PT‐VWD from type 2B VWD and GP1BA nomenclature issues response to Othman
  246. The genetic basis of human athletic performance. Why are psychological components so often overlooked?
  247. Antiphospholipid Antibodies and the Antiphospholipid Syndrome II: Limitations, Standardization, and Clinical Utility of Laboratory Testing
  248. Laboratory Testing and Identification of Antiphospholipid Antibodies and the Antiphospholipid Syndrome: A Potpourri of Problems, a Compilation of Possible Solutions
  249. A Consensus Approach to the Formulation of Guidelines for Laboratory Testing and Reporting of Antiphospholipid Antibody Assays
  250. The paradoxical relationship between serum uric acid and cardiovascular disease
  251. Cardiac biomarkers in pulmonary embolism
  252. Stability of coagulation assays performed in plasma from citrated whole blood transported at ambient temperature: Only a part of the story
  253. Potential benefits of improved protein intake in older people
  254. Clinical Features, Diagnosis, and Management of the Antiphospholipid Syndrome
  255. Professor Ronald A. Asherson, M.D. (Hon), F.R.C.P., M.D., F.A.C.P., F.C.P., F.A.C.R., Dip. O&G (Hon) [1934–2008]
  256. Antiphospholipid Antibodies and the Antiphospholipid Syndrome I: Pathogenesis, Clinical Features, Diagnosis, and Management
  257. The LOC387715 Polymorphism, Inflammatory Markers, Smoking, and Age-Related Macular Degeneration
  258. von Willebrand disease, type 2B: A diagnosis more elusive than previously thought
  259. Welcome to Seminars in Thrombosis and Hemostasis -2008!
  260. Measuring the Quality of Journals and Journal Articles: The Impact Factor Tells but a Portion of the Story
  261. Hot Topics II: An Editorial Collection of Current Issues and Controversies in Thrombosis and Hemostasis
  262. Phenotypic Identification of Platelet-Type von Willebrand Disease and Its Discrimination from Type 2B von Willebrand Disease: A Question of 2B or Not 2B? A Story of Nonidentical Twins? Or Two Sides of a Multidenominational or Multifaceted Primary-Hemos...
  263. Detection of duplicates and redundancies. A major responsibility of peer-reviewers?
  264. Help me, Doctor! My D-dimer is raised
  265. Protein Z is reduced in chronic kidney disease and not elevated in patients on haemodialysis
  266. Air pollution and coagulation testing: A new source of biological variability?
  267. A practical approach to instrument selection, evaluation, basic financial management and implementation in pathology and research
  268. The Diagnostic Dilemma: Dual Presentations of Clinical Mucosal Bleeding and Venous Thrombosis Associated with the Presence of Thrombophilia Markers and Mild Reduction in von Willebrand Factor
  269. Hot Topics I: A Potpourri of Current Issues and Controversies in Thrombosis and Hemostasis
  270. An Update on the von Willebrand Factor Collagen Binding Assay: 21 Years of Age and Beyond Adolescence but Not Yet a Mature Adult
  271. Hemostatic Dysfunction Associated with Endocrine Disorders as a Major Risk Factor and Cause of Human Morbidity and Mortality: A Comprehensive Meta-review
  272. Time to Think Outside the Box? Proposals for a New Approach to Future Pharmacokinetic Studies of von Willebrand Factor Concentrates in People with von Willebrand Disease
  273. Differential identification of a rare form of platelet‐type (pseudo‐) von Willebrand disease (VWD) from Type 2B VWD using a simplified ristocetin‐induced‐platelet‐agglutination mixing assay and confirmed by genetic analysis
  274. Mis-identification of factor inhibitors by diagnostic haemostasis laboratories: recognition of pitfalls and elucidation of strategies. A follow up to a large multicentre evaluation
  275. More on the impact factor and thrombosis and haemostasis journals: Benefits and limitations
  276. 2B or not 2B? Disparate discrimination of functional VWF discordance using different assay panels or methodologies may lead to success or failure in the early identification of type 2B VWD
  277. Utility of the PFA-100 as a screening test of platelet function: an audit of haemostasis laboratories in Australia and New Zealand
  278. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study
  279. Standardization, Quality Assurance, and Emerging Diagnostic Technologies in Hemostasis
  280. Emerging Technologies and Quality Assurance in Hemostasis: A Review of Findings from the Royal College of Pathologists of Australasia Quality Assurance Program
  281. Standardization, Regulation, Quality Assurance and Emerging Technologies in Hemostasis: Issues, Controversies, Benefits, and Limitations
  282. A Review of β 2 -Glycoprotein-I Antibody Testing Results From a Peer-Driven Multilaboratory Quality Assurance Program
  283. Investigating people with mucocutaneous bleeding suggestive of primary hemostatic defects: a low likelihood of a definitive diagnosis?
  284. Preanalytical variables in coagulation testing
  285. Thrombophilia and Cerebral Vein Thrombosis
  286. Increased Propensity to Bruising in Red-Haired Females: A Possible Role for von Willebrand Factor?
  287. 2B or not 2B? Differential identification of type 2B, versus pseudo‐, von Willebrand disease – response to Whalley and Perry
  288. Laboratory Monitoring of Therapy in von Willebrand Disease: Efficacy of the PFA-100 and von Willebrand Factor:Collagen-Binding Activity as Coupled Strategies
  289. More on: platelet function analyser (PFA)‐100® closure time in the evaluation of platelet disorders and platelet function
  290. 2B or not 2B? Differential identification of type 2B, versus pseudo‐von Willebrand disease
  291. Laboratory Identification of von Willebrand Disease: Technical and Scientific Perspectives
  292. The Utility of the PFA-100 in the Identification of von Willebrand Disease: A Concise Review
  293. Reducing Errors in Identification of von Willebrand Disease: The Experience of the Royal College of Pathologists of Australasia Quality Assurance Program
  294. More on ‘universal’versus‘selected’ screening for thrombophilia: the hidden costs of false‐positive diagnosis
  295. Identification of factor inhibitors by diagnostic haemostasis laboratories. A large multi-centre evaluation
  296. Unrecognized pellagra masquerading as odynophagia
  297. Effect of overnight 4°C storage of whole blood on von Willebrand factor
  298. Activated protein C resistance: The influence of ABO-blood group, gender and age
  299. Cold storage of citrated whole blood induces drastic time-dependent losses in factor VIII and von Willebrand factor: potential for misdiagnosis of haemophilia and von Willebrand disease
  300. Reassessment of ABO Blood Group, Sex, and Age on Laboratory Parameters Used to Diagnose von Willebrand Disorder
  301. Cross-laboratory audit of normal reference ranges and assessment of ABO blood group, gender and age on detected levels of plasma coagulation factors
  302. How Useful is the Monitoring of (Low Molecular Weight) Heparin Therapy by Anti-Xa Assay? A Laboratory Perspective
  303. Laboratory Identification of Familial Thrombophilia: Do the Pitfalls Exceed the Benefits? A Reassessment of ABO-Blood Group, Gender,Age, and other Laboratory Parameters on the Potential Influence on a Diagnosis of Protein C, Protein S, and Antithromb
  304. A Diet Rich in High-Oleic-Acid Sunflower Oil Favorably Alters Low-Density Lipoprotein Cholesterol, Triglycerides, and Factor VII Coagulant Activity
  305. An international survey of current practice in the laboratory assessment of anticoagulant therapy with heparin
  306. Laboratory Diagnosis of von Willebrand Disorder: Use of Multiple Functional Assays Reduces Diagnostic Error Rates
  307. Diagnostic Issues in Thrombophilia: A Laboratory Scientist's View
  308. External Quality Assurance of DNA Testing for Thrombophilia Mutations
  309. Development of Consensus Guidelines for Anticardiolipin and Lupus Anticoagulant Testing
  310. Learning from Peer Assessment: The Role of the External Quality Assurance Multilaboratory Thrombophilia Test Process
  311. Multilaboratory Testing of Thrombophilia: Current and Past Practice in Australasia as Assessed through the Royal College of Pathologists of Australasia Quality Assurance Program for Hematology
  312. A Multilaboratory Peer Assessment Quality Assurance Program-Based Evaluation of Anticardiolipin Antibody, and beta 2 -Glycoprotein I Antibody Testing
  313. Factor V inhibitors
  314. Potential Laboratory Misdiagnosis of Hemophilia and von Willebrand Disorder Owing to Cold Activation of Blood Samples for Testing
  315. Evaluation of primary haemostasis in people with neurofibromatosis type 1
  316. A multi-centre evaluation of the intra-assay and inter-assay variation of commercial and in-house anti-cardiolipin antibody assays
  317. Consensus guidelines on anti-cardiolipin antibody testing and reporting
  318. Laboratory Diagnosis of von Willebrand Disorder
  319. Assessing the Usefulness of Anticardiolipin Antibody Assays
  320. Clinical application of the PFA-100®
  321. Identification of von Willebrand Disease Type 2N (Normandy) in Australia
  322. Treatment of two patients with acquired factor VIII inhibitors using cyclophosphamide and prednisone
  323. von Willebrand Factor Collagen-Binding (Activity) Assay in the Diagnosis of von Willebrand Disease: A 15-Year Journey
  324. A 9-year retrospective assessment of laboratory testing for activated protein C resistance: evolution of a novel approach to thrombophilia investigations
  325. Appropriate laboratory assessment as a critical facet in the proper diagnosis and classification of von Willebrand disorder
  326. Utility of the PFA‐100® for assessing bleeding disorders and monitoring therapy: a review of analytical variables, benefits and limitations
  327. Possibility of potential VWD misdiagnosis or misclassification using LIA technology and due to presence of rheumatoid factor
  328. Detection of von Willebrand Disorder and Identification of Qualitative von Willebrand Factor Defects Direct Comparison of Commercial ELISA-Based von Willebrand Factor Activity Options
  329. Is the activity of VWF increased in type II diabetes mellitus?
  330. Sulfatide-Binding Assay for von Willebrand Factor
  331. Type 2B von Willebrand's disease in thirteen individuals from five unrelated Australian families: Phenotype and genotype correlations
  332. Possibility of potential VWD misdiagnosis or misclassification using LIA technology and due to presence of rheumatoid factor
  333. Laboratory assessment as a critical component of the appropriate diagnosis and sub-classification of von Willebrand’s disease
  334. Use of a novel platelet function analyzer (PFA‐100™) with high sensitivity to disturbances in von willebrand factor to screen for von willebrand's disease and other disorders
  335. Use of a novel platelet function analyzer (PFA-100?) with high sensitivity to disturbances in von willebrand factor to screen for von willebrand's disease and other disorders
  336. Mesenteric vein thrombosis secondary to combined protein C deficiency and double heterozygosity for factor V leiden and prothrombin G20210A
  337. Mesenteric vein thrombosis secondary to combined protein C deficiency and double heterozygosity for factor V leiden and prothrombin G20210A
  338. Identification and characterization of a novel mutation in von Willebrand factor causing type 2B von Willebrand's disease
  339. Clinical utility of anticardiolipin antibody assays: high inter-laboratory variation and limited consensus by participants of external quality assurance programs signals a cautious approach
  340. Comparison of the effects of two low fat diets with different α-linolenic:linoleic acid ratios on coagulation and fibrinolysis
  341. A Simple, Whole Blood Method for Assessment of Platelet Function
  342. Biliary fibronectin: Significant limitation as a diagnostic tool in malignant biliary obstruction
  343. The MDA-180 coagulation analyser: a laboratory evaluation
  344. Laboratory assays for von Willebrand Factor: relative contribution to the diagnosis of von Willebrand’s disease
  345. Laboratory assessment of von Willebrand factor: differential influence of prolonged ambient temperature specimen storage on assay results
  346. Cardiovascular Risk Factors and Dietary Plant Omega-3 Verus Omega-6 Fatty Acids
  347. MUTATIONS IN A SUBGROUP OF PATIENTS WITH MILD HAEMOPHILIA A AND A FAMILIAL DISCREPANCY BETWEEN THE ONE‐STAGE AND TWO‐STAGE FACTOR VIII:C METHODS
  348. A survey of heparin monitoring in australasia
  349. Aminopeptidase-N (CD13; gp 150): Contrasting patterns of enzymatic activity in blood from patients with myeloid or lymphoid leukemia
  350. Attenuated platelet sensitivity to collagen in patients with neurofibromatosis type 1
  351. von Willebrand's disease: Use of collagen binding assay provides potential improvement to laboratory monitoring of desmopressin (DDAVP) therapy
  352. Differential expression of surface antigens on activated endothelium
  353. The hepatobiliary disease marker serum alanine aminopeptidase predominantly comprises an isoform of the haematological myeloid differentiation antigen and leukaemia marker CD-13/gp150
  354. Acidified Chloroquine Treatment for the Removal of Class I HLA Antigens
  355. Von willebrand's disease: laboratory investigation using an improved functional assay for von willebrand factor
  356. Heparin - induced thrombocytopenia: laboratory investigation and confirmation of diagnosis
  357. CD‐13 (‘gp150’; aminopeptidase‐N): Co‐expression on endothelial and haemopoietic cells with conservation of functional activity
  358. Co‐expression of haemopoietic antigens on vascular endothelial cells: a detailed phenotypic analysis
  359. Immunophenotype of clonogenic cells in myeloid leukaemia
  360. Coexpression of p165 myeloid surface antigen and terminal deoxynucleotidyl transferase: A comparison of acute myeloid leukaemia and normal bone marrow cells
  361. Myeloid progenitor surface antigen identified by monoclonal antibody
  362. Human myeloid differentiation antigens identified by monoclonal antibodies: expression on leukemic cells